Rinfret Stéphane, Ribeiro Henrique Barbosa, Nguyen Can Manh, Nombela-Franco Luis, Ureña Marina, Rodés-Cabau Josep
Multidisciplinary Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec (Quebec Heart & Lung Institute), Laval University, Quebec City, Quebec, Canada.
Multidisciplinary Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec (Quebec Heart & Lung Institute), Laval University, Quebec City, Quebec, Canada.
Am J Cardiol. 2014 Nov 1;114(9):1354-60. doi: 10.1016/j.amjcard.2014.07.067. Epub 2014 Aug 12.
New techniques involving dissection of the subintimal space and re-entry into the true lumen increase success rates in chronic total occlusion (CTO) percutaneous coronary intervention (PCI). However, their long-term safety and efficacy were unknown. This study included a series of consecutive patients who underwent CTO PCI. All patients who did not present events were contacted 12 to 18 months after their PCI. The combined incidence of cardiac death, myocardial infarction, ischemia-driven target-vessel revascularization (TVR), or reocclusion was assessed as our primary outcome. From January 2010 to January 2013, of 212 CTOs treated in our CTO program, 192 (91%) were successfully opened (in 179 patients). Follow-up data were available for 187 CTOs (97.4%), with 82 (44%) that were opened with dissection re-entry and 105 (56%) with conventional wire escalation techniques. At a median follow-up of 398 days, the primary outcome occurred in 18 of 179 CTOs treated (10.7%), driven by TVR. No patient died from cardiac causes. Eleven CTOs (15.2%) treated with dissection re-entry versus 7 CTOs (7.3%) treated with wire escalation presented with the primary outcome (p = 0.17). With multivariate adjustment, dissection re-entry techniques had no significant impact on outcomes. However, treatment of an in-stent occlusion was independently associated with TVR (hazards ratio >6.0, p <0.001). In conclusion, dissection re-entry techniques have minimal impact on long-term outcomes after CTO PCI, which are favorable in most patients. However, treatment of an in-stent occlusion and use of sirolimus-eluting stent were predictors of subsequent adverse outcomes.
涉及内膜下空间剥离和重新进入真腔的新技术提高了慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)的成功率。然而,它们的长期安全性和有效性尚不清楚。本研究纳入了一系列连续接受CTO PCI的患者。所有未出现事件的患者在PCI术后12至18个月接受随访。评估心脏死亡、心肌梗死、缺血驱动的靶血管血运重建(TVR)或再闭塞的联合发生率作为我们的主要结局。从2010年1月至2013年1月,在我们的CTO项目中治疗的212例CTO中,192例(91%)成功开通(179例患者)。187例CTO(97.4%)有随访数据,其中82例(44%)通过剥离再进入开通,105例(56%)采用传统导丝升级技术开通。在中位随访398天时,179例接受治疗的CTO中有18例(10.7%)出现主要结局,由TVR驱动。无患者死于心脏原因。采用剥离再进入治疗的11例CTO(15.2%)与采用导丝升级治疗的7例CTO(7.3%)出现主要结局(p = 0.17)。经过多变量调整,剥离再进入技术对结局无显著影响。然而,支架内闭塞的治疗与TVR独立相关(风险比>6.0,p<0.001)。总之,剥离再进入技术对CTO PCI后的长期结局影响极小,大多数患者的结局良好。然而,支架内闭塞的治疗和西罗莫司洗脱支架的使用是后续不良结局的预测因素。